Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

96 Solvay Global Annual Report 2005 Solvay Participations France S.A., Paris 100 - Solvay Pharma S.A.S., Suresnes 99.9 Ph Solvay Pharmaceuticals S.A.S., Suresnes 99.9 Ph Solvay Solexis S.A.S., Paris 100 Pl Solvay - Spécialités - France S.A.S., Paris 100 Ch Vivalsol S.A.S., Paris ITALY 100 Ph Alkor Draka Italia S.r.l., Milano 100 Pl Fournier Pharma S.p.A, Segrate 100 Ph GOR Applicazioni Speciali S.p.A., Buriasco 100 Pl SIS Italia S.p.A., Rosignano 100 - Società Elettrochimica Solfuri e Cloroderivati (ELESO) S.p.A., Milano 100 Ch Società Generale per l’Industria della Magnesia (SGIM) S.p.A., Angera 100 Ch Solvay Bario e Derivati S.p.A., Massa 100 Ch Solvay Benvic - Italia S.p.A, Rosignano 100 Pl Solvay Chimica Italia S.p.A., Milano 100 Ch Solvay Chimica Bussi S.p.A., Rosignano 100 Ch Solvay Fluor Italia S.p.A., Rosignano 100 Ch Solvay Finanziaria S.p.A., Milano 100 - Solvay Padanaplast SpA, Roccabianca 100 Pl Solvay Pharma S.p.A., Grugliasco 100 Ph Solvay Solexis S.p.A., Milano GERMANY 100 Pl Solvay GmbH, Hannover 100 - Alkor GmbH Kunststoffe, München 100 Pl Alkor Folien GmbH, Thansau 100 Pl Cavity GmbH & Co KG, Hannover 100 Ch Fournier Pharma GmbH, Thansau 100 Ph Girindus AG, Bensberg 74.1 Ch Hispavic GmbH, Hannover 100 Pl Kali-Chemie AG, Hannover 100 - Solvay Organics GmbH, Hannover 100 Ch Salzgewinnungsgesellschaft Westfalen mbH & Co KG, Epe 65 Ch Solvay Advanced Polymers GmbH, Hannover 100 Pl Solvay Arzneimittel GmbH, Hannover 100 Ph Solvay Chemicals GmbH, Hannover 100 Ch Solvay Fluor GmbH, Hannover 100 Ch Solvay Infra GmbH, Hannover 100 Ch Solvay Infra Bad Hoenningen GmbH, Hannover 100 Ch Solvay Interox Bitterfeld GmbH, Bitterfeld 100 Ch Solvay Kali-Chemie Holding GmbH 100 - Solvay Management Support GmbH, Hannover 100 - Solvay Pharmaceuticals GmbH, Hannover 100 Ph
Solvay Salz Holding GmbH, Hannover 100 Ch Sovlay Salz Beteiligungs GmbH & Co KG, Hannover 100 Ch Solvay Verwaltungs-und Vermittlungs GmbH, Hannover SPAIN 100 - Alkor Draka Iberica S.A., Barcelona 100 Pl Electrolisis de Torrelavega A.E.I., Torrelavega 100 Ch Laboratorios Fournier S.A., Tres Cantos 100 Ph Solvay Benvic Iberica S.A., Barcelona 100 Pl Solvay Ibérica S.L., Barcelona 100 - Solvay Fluor Iberica S.A., Tarragona 100 Ch Solvay Interox S.A., Barcelona 100 Ch Solvay Participaciones S.A., Barcelona 100 - Solvay Pharma S.A., Barcelona 100 Ph Solvay Quimica S.L., Barcelona SWITZERLAND 100 Ch Girindus S.A., Fribourg 74.1 Ch Solvay (Schweiz) AG, Zurzach 100 Ch Solvay Pharmaceuticals Marketing & Licensing AG, Allschwil 100 Ph Solvay Pharma AG, Bern PORTUGAL 100 Ph 3S Solvay Shared Services-Sociedade de Serviços Partilhados Unipessoal Lda, Lisboa 100 - Fournier Farmaceutica S.A., Lisboa 100 Ph Solvay Farma Lda, Lisboa 100 Ph Solvay Interox - Produtos Peroxidados S.A., Lisboa 100 Ch Solvay Portugal - Produtos Quimicos S.A., Lisboa AUSTRIA 100 Ch Solvay Österreich GmbH, Wien 100 Ch Solvay Pharma GmbH, Klosterneuburg GREAT BRITAIN 100 Ph Alkor Draka (UK) Ltd, Watford 100 Pl Alkor Draka Limited, Cramlington 100 Pl Founier Pharmaceuticals Ltd, Slough 100 Ph Solvay Chemicals Ltd, Warrington 100 Ch Solvay Healthcare Ltd, Southampton 100 Ph Solvay Interox Ltd, Warrington 100 Ch Solvay UK Holding Company Ltd, Warrington 100 - Solvay Speciality Chemicals Ltd, Warrington IRELAND 100 Ch Fournier Laboratories Ireland Ltd, Cork 100 Ph Solvay Healthcare Ltd , Dubin 100 Ph Solvay Finance Ireland Ltd , Dublin DENMARK 100 - Alkor Draka Nordic K/S, Albertslund 100 Pl Solvay Global Annual Report 2005 97
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48:
Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97 and 98: PORTUGAL Fournier Farmaceutica Port
Page 99: List of fully consolidated Group co
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113 and 114: Contacts: The Investor Relations Te
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?